Home > > > Report Detail

Global Neoantigen Cancer Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 05-Dec-2022
No. of pages: 113
Inquire Before Buying

It is through the use of tumor cell-associated antigens to awaken the body's immune system against cancer.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Neoantigen Cancer Vaccine estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.

The USA market for Neoantigen Cancer Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Neoantigen Cancer Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Neoantigen Cancer Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key companies of Neoantigen Cancer Vaccine include Roche, Medimmune, Merck, Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics and Nouscom, etc. In 2021, the global top five players had a share approximately % in terms of revenue.

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Neoantigen Cancer Vaccine companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Neoantigen Cancer Vaccine market. Further, it explains the major drivers and regional dynamics of the global Neoantigen Cancer Vaccine market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Roche

- Medimmune

- Merck

- Advaxis

- Agenus

- Genocea

- Gritstone Oncology

- Neon Therapeutics

- Nouscom

- OSE Immunotherapeutics

- Medigene

- Vaccibody

- Brightpath Biotherapeutics

- Geneos Therapeutics

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Neoantigen Cancer Vaccine Segment by Type

- Personalized Vaccine

- Off-the-shelf Neovaccines

Neoantigen Cancer Vaccine Segment by Application

- Hospital

- Clinic

- Others

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Neoantigen Cancer Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Neoantigen Cancer Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Neoantigen Cancer Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neoantigen Cancer Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neoantigen Cancer Vaccine revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Neoantigen Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Neoantigen Cancer Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Roche, Medimmune, Merck, Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics and Nouscom, etc.

Global Neoantigen Cancer Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Neoantigen Cancer Vaccine Market Size (2017-2028)
2.2 Neoantigen Cancer Vaccine Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Neoantigen Cancer Vaccine Market Size by Region (2017-2022)
2.4 Global Neoantigen Cancer Vaccine Market Size Forecast by Region (2023-2028)
2.5 Global Top Neoantigen Cancer Vaccine Countries Ranking by Market Size
3 Neoantigen Cancer Vaccine Competitive by Company
3.1 Global Neoantigen Cancer Vaccine Revenue by Players
3.1.1 Global Neoantigen Cancer Vaccine Revenue by Players (2017-2022)
3.1.2 Global Neoantigen Cancer Vaccine Market Share by Players (2017-2022)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2021
3.5 Global Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Revenue by Type (2017-2022)
4.2 Global Neoantigen Cancer Vaccine Forecasted Revenue by Type (2023-2028)
5 Global Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neoantigen Cancer Vaccine Revenue by Company (2020-2022)
6.2 North America Neoantigen Cancer Vaccine Revenue by Type (2017-2028)
6.3 North America Neoantigen Cancer Vaccine Revenue by Application (2017-2028)
6.4 North America Neoantigen Cancer Vaccine Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Revenue by Company (2020-2022)
7.2 Europe Neoantigen Cancer Vaccine Revenue by Type (2017-2028)
7.3 Europe Neoantigen Cancer Vaccine Revenue by Application (2017-2028)
7.4 Europe Neoantigen Cancer Vaccine Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Neoantigen Cancer Vaccine Revenue by Company (2020-2022)
8.2 Asia Pacific Neoantigen Cancer Vaccine Revenue by Type (2017-2028)
8.3 Asia Pacific Neoantigen Cancer Vaccine Revenue by Application (2017-2028)
8.4 Asia Pacific Neoantigen Cancer Vaccine Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Revenue by Company (2020-2022)
9.2 Latin America Neoantigen Cancer Vaccine Revenue by Type (2017-2028)
9.3 Latin America Neoantigen Cancer Vaccine Revenue by Application (2017-2028)
9.4 Latin America Neoantigen Cancer Vaccine Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neoantigen Cancer Vaccine Revenue by Company (2020-2022)
10.2 Middle East and Africa Neoantigen Cancer Vaccine Revenue by Type (2017-2028)
10.3 Middle East and Africa Neoantigen Cancer Vaccine Revenue by Application (2017-2028)
10.4 Middle East and Africa Neoantigen Cancer Vaccine Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Products and Services
11.1.4 Roche Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.1.5 Roche Neoantigen Cancer Vaccine SWOT Analysis
11.1.6 Roche Recent Developments
11.2 Medimmune
11.2.1 Medimmune Company Details
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Products and Services
11.2.4 Medimmune Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.2.5 Medimmune Neoantigen Cancer Vaccine SWOT Analysis
11.2.6 Medimmune Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Products and Services
11.3.4 Merck Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.3.5 Merck Neoantigen Cancer Vaccine SWOT Analysis
11.3.6 Merck Recent Developments
11.4 Advaxis
11.4.1 Advaxis Company Details
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Products and Services
11.4.4 Advaxis Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.4.5 Advaxis Neoantigen Cancer Vaccine SWOT Analysis
11.4.6 Advaxis Recent Developments
11.5 Agenus
11.5.1 Agenus Company Details
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Products and Services
11.5.4 Agenus Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.5.5 Agenus Neoantigen Cancer Vaccine SWOT Analysis
11.5.6 Agenus Recent Developments
11.6 Genocea
11.6.1 Genocea Company Details
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Products and Services
11.6.4 Genocea Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.6.5 Genocea Neoantigen Cancer Vaccine SWOT Analysis
11.6.6 Genocea Recent Developments
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Details
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Products and Services
11.7.4 Gritstone Oncology Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.7.5 Gritstone Oncology Neoantigen Cancer Vaccine SWOT Analysis
11.7.6 Gritstone Oncology Recent Developments
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Details
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Products and Services
11.8.4 Neon Therapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.8.5 Neon Therapeutics Neoantigen Cancer Vaccine SWOT Analysis
11.8.6 Neon Therapeutics Recent Developments
11.9 Nouscom
11.9.1 Nouscom Company Details
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Products and Services
11.9.4 Nouscom Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.9.5 Nouscom Neoantigen Cancer Vaccine SWOT Analysis
11.9.6 Nouscom Recent Developments
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Details
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Products and Services
11.10.4 OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.10.5 OSE Immunotherapeutics Neoantigen Cancer Vaccine SWOT Analysis
11.10.6 OSE Immunotherapeutics Recent Developments
11.11 Medigene
11.11.1 Medigene Company Details
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Products and Services
11.11.4 Medigene Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.11.5 Medigene Recent Developments
11.12 Vaccibody
11.12.1 Vaccibody Company Details
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Products and Services
11.12.4 Vaccibody Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.12.5 Vaccibody Recent Developments
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Details
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Products and Services
11.13.4 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.13.5 Brightpath Biotherapeutics Recent Developments
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Details
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Products and Services
11.14.4 Geneos Therapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.14.5 Geneos Therapeutics Recent Developments
12 Neoantigen Cancer Vaccine Market Dynamics
12.1 Neoantigen Cancer Vaccine Market Trends
12.2 Neoantigen Cancer Vaccine Market Drivers
12.3 Neoantigen Cancer Vaccine Market Challenges
12.4 Neoantigen Cancer Vaccine Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Neoantigen Cancer Vaccine Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 6. Global Neoantigen Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 8. Global Neoantigen Cancer Vaccine Revenue by Players (2017-2022) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Players (2017-2022)
Table 10. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Table 11. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2021
Table 12. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2017-2022)
Table 13. Key Players Headquarters and Area Served
Table 14. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 15. Date of Key Manufacturers Enter into Neoantigen Cancer Vaccine Market
Table 16. Mergers & Acquisitions, Expansion Plans
Table 17. Global Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 18. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2022)
Table 19. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 20. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2023-2028)
Table 21. Global Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 22. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2022)
Table 23. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2023-2028)
Table 25. North America Neoantigen Cancer Vaccine Revenue by Company (2020-2022) & (US$ Million)
Table 26. North America Neoantigen Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 27. North America Neoantigen Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 28. North America Neoantigen Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 29. North America Neoantigen Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 30. North America Neoantigen Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 31. North America Neoantigen Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 32. Europe Neoantigen Cancer Vaccine Revenue by Company (2020-2022) & (US$ Million)
Table 33. Europe Neoantigen Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 34. Europe Neoantigen Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 35. Europe Neoantigen Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 36. Europe Neoantigen Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 37. Europe Neoantigen Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 38. Europe Neoantigen Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 39. Asia Pacific Neoantigen Cancer Vaccine Revenue by Company (2020-2022) & (US$ Million)
Table 40. Asia Pacific Neoantigen Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 41. Asia Pacific Neoantigen Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 42. Asia Pacific Neoantigen Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 43. Asia Pacific Neoantigen Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 44. Asia Pacific Neoantigen Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 45. Asia Pacific Neoantigen Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 46. Latin America Neoantigen Cancer Vaccine Revenue by Company (2020-2022) & (US$ Million)
Table 47. Latin America Neoantigen Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. Latin America Neoantigen Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. Latin America Neoantigen Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 50. Latin America Neoantigen Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 51. Latin America Neoantigen Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 52. Latin America Neoantigen Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 53. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Company (2020-2022) & (US$ Million)
Table 54. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 55. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Neoantigen Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 60. Roche Company Details
Table 61. Roche Business Overview
Table 62. Roche Neoantigen Cancer Vaccine Product and Services
Table 63. Roche Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 64. Roche Neoantigen Cancer Vaccine SWOT Analysis
Table 65. Roche Recent Developments
Table 66. Medimmune Company Details
Table 67. Medimmune Business Overview
Table 68. Medimmune Neoantigen Cancer Vaccine Product and Services
Table 69. Medimmune Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 70. Medimmune Neoantigen Cancer Vaccine SWOT Analysis
Table 71. Medimmune Recent Developments
Table 72. Merck Company Details
Table 73. Merck Business Overview
Table 74. Merck Neoantigen Cancer Vaccine Product and Services
Table 75. Merck Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 76. Merck Neoantigen Cancer Vaccine SWOT Analysis
Table 77. Merck Recent Developments
Table 78. Advaxis Company Details
Table 79. Advaxis Business Overview
Table 80. Advaxis Neoantigen Cancer Vaccine Product and Services
Table 81. Advaxis Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 82. Advaxis Neoantigen Cancer Vaccine SWOT Analysis
Table 83. Advaxis Recent Developments
Table 84. Agenus Company Details
Table 85. Agenus Business Overview
Table 86. Agenus Neoantigen Cancer Vaccine Product and Services
Table 87. Agenus Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 88. Agenus Neoantigen Cancer Vaccine SWOT Analysis
Table 89. Agenus Recent Developments
Table 90. Genocea Company Details
Table 91. Genocea Business Overview
Table 92. Genocea Neoantigen Cancer Vaccine Product and Services
Table 93. Genocea Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 94. Genocea Neoantigen Cancer Vaccine SWOT Analysis
Table 95. Genocea Recent Developments
Table 96. Gritstone Oncology Company Details
Table 97. Gritstone Oncology Business Overview
Table 98. Gritstone Oncology Neoantigen Cancer Vaccine Product and Services
Table 99. Gritstone Oncology Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 100. Gritstone Oncology Neoantigen Cancer Vaccine SWOT Analysis
Table 101. Gritstone Oncology Recent Developments
Table 102. Neon Therapeutics Company Details
Table 103. Neon Therapeutics Business Overview
Table 104. Neon Therapeutics Neoantigen Cancer Vaccine Product and Services
Table 105. Neon Therapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 106. Neon Therapeutics Neoantigen Cancer Vaccine SWOT Analysis
Table 107. Neon Therapeutics Recent Developments
Table 108. Nouscom Company Details
Table 109. Nouscom Business Overview
Table 110. Nouscom Neoantigen Cancer Vaccine Product and Services
Table 111. Nouscom Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 112. Nouscom Neoantigen Cancer Vaccine SWOT Analysis
Table 113. Nouscom Recent Developments
Table 114. OSE Immunotherapeutics Company Details
Table 115. OSE Immunotherapeutics Business Overview
Table 116. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product and Services
Table 117. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 118. OSE Immunotherapeutics Neoantigen Cancer Vaccine SWOT Analysis
Table 119. OSE Immunotherapeutics Recent Developments
Table 120. Medigene Company Details
Table 121. Medigene Business Overview
Table 122. Medigene Neoantigen Cancer Vaccine Product and Services
Table 123. Medigene Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 124. Medigene Recent Developments
Table 125. Vaccibody Company Details
Table 126. Vaccibody Business Overview
Table 127. Vaccibody Neoantigen Cancer Vaccine Product and Services
Table 128. Vaccibody Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 129. Vaccibody Recent Developments
Table 130. Brightpath Biotherapeutics Company Details
Table 131. Brightpath Biotherapeutics Business Overview
Table 132. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product and Services
Table 133. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 134. Brightpath Biotherapeutics Recent Developments
Table 135. Geneos Therapeutics Company Details
Table 136. Geneos Therapeutics Business Overview
Table 137. Geneos Therapeutics Neoantigen Cancer Vaccine Product and Services
Table 138. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 139. Geneos Therapeutics Recent Developments
Table 140. Neoantigen Cancer Vaccine Market Trends
Table 141. Neoantigen Cancer Vaccine Market Drivers
Table 142. Neoantigen Cancer Vaccine Market Challenges
Table 143. Neoantigen Cancer Vaccine Market Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Sales Market Share by Type: 2021 VS 2028
Figure 2. Personalized Vaccine Features
Figure 3. Off-the-shelf Neovaccines Features
Figure 4. Global Neoantigen Cancer Vaccine Sales Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Neoantigen Cancer Vaccine Report Years Considered
Figure 9. Global Neoantigen Cancer Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Neoantigen Cancer Vaccine Market Size 2017-2028 (US$ Million)
Figure 11. Global Neoantigen Cancer Vaccine Market Size Market Share by Region: 2021 VS 2028
Figure 12. Global Neoantigen Cancer Vaccine Revenue Market Share by Region in 2017 VS 2022
Figure 13. Global Top 10 Neoantigen Cancer Vaccine Countries Ranking by Market Size (US$ Million) in 2021
Figure 14. Global Neoantigen Cancer Vaccine Market Share by Players in 2021
Figure 15. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2021
Figure 17. North America Neoantigen Cancer Vaccine Revenue Market Share by Company in 2021
Figure 18. North America Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 19. North America Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 20. North America Neoantigen Cancer Vaccine Revenue Share by Country (2017-2028)
Figure 21. U.S. Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 22. Canada Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 23. Europe Neoantigen Cancer Vaccine Revenue Market Share by Company in 2021
Figure 24. Europe Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 25. Europe Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 26. Europe Neoantigen Cancer Vaccine Revenue Share by Country (2017-2028)
Figure 27. Germany Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 28. France Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 29. U.K. Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 30. Italy Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 31. Russia Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Neoantigen Cancer Vaccine Revenue Market Share by Company in 2021
Figure 33. Asia Pacific Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 34. Asia Pacific Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 35. Asia Pacific Neoantigen Cancer Vaccine Revenue Share by Region (2017-2028)
Figure 36. China Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 37. Japan Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 38. South Korea Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 39. India Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 40. Australia Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 41. Taiwan Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 42. Indonesia Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 43. Thailand Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 44. Malaysia Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 45. Philippines Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 46. Vietnam Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 47. Latin America Neoantigen Cancer Vaccine Revenue Market Share by Company in 2021
Figure 48. Latin America Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 49. Latin America Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 50. Latin America Neoantigen Cancer Vaccine Revenue Share by Country (2017-2028)
Figure 51. Mexico Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 52. Brazil Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 53. Argentina Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 54. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Company in 2021
Figure 55. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2028)
Figure 56. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 57. Middle East and Africa Neoantigen Cancer Vaccine Revenue Share by Country (2017-2028)
Figure 58. Turkey Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 59. Saudi Arabia Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. UAE Neoantigen Cancer Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 62. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 63. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 64. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 65. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 66. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 67. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 68. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 69. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 70. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 71. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 72. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 73. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 74. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
  • Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
    Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118
    The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......
  • Global Non-imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90
    The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
  • Global PCR Equipment Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77
    The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......
  • Global Disposable Sterile Syringes and Needles Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109
    The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......
  • Global Orthopaedic Power Tools Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
  • Global Cerebrospinal Fluid Management Devices Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
  • Global CAD & CAM Milling Burs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
  • Global Artificial Teeth Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98
    The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs